Investec reaffirms Consort Medical at 'buy', warns of weakening Euro

Investec has kept Consort Medical's rating at 'buy', and upped its price target from 928p to 1033p. Despite being optimistic about the healthcare firm's operational performance, Investec is concerned about the headwind posed by a strengthening Euro.Investec said in a note Consort's revenue of £184.8m had surpassed its estimates by 2.2%, driven by a solid underlying progression."Operationally, Consort is performing well and, with a deep pipeline of opportunities to capitalise upon, we think growth could be significantly enhanced over the medium term."Investec noted how Consort's Aesica division is heavily exposed to the Euro, which makes up more than half its revenues.Shares in the company were at 930.58, up 0.33% on Tuesday at 9:35.